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Hypertension remains a major contributor to the global burden of disease. The measurement of blood pressure continues to have pitfalls related to
bothphysiological aspects andacutevariation.Asthe leftventricle (LV)remainsoneofthemain targetorgansofhypertension, andechocardiographic
measures of structure and function carry prognostic information in this setting, the development of a consensus position on the use of echocardi-
ography in this setting is important. Recent developments in the assessment of LV hypertrophy and LV systolic and diastolic function have prompted
the preparation of this document. The focus of this work is on the cardiovascular responses to hypertension rather than the diagnosis of secondary
hypertension. Sections address the pathophysiology of the cardiac and vascular responses to hypertension, measurement of LV mass, geometry, and
function, as well as effects of treatment.
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Pathophysiology of cardiac
responses to hypertension
Left ventricular hypertrophy
Size and geometry of the normal heart
The main contribution of echocardiography to the management of
hypertension is the assessment of left ventricular (LV) mass (LVM).
Body habitus represents one of several factors that confound the
association between hypertension and LVM. However, cardiac size
is influenced by body size, and for any given size, men have larger
hearts than women, athletes have larger hearts than non-athletes,
and obese subjects have larger hearts than non-obese subjects.1
LVM and volumes bear an approximately quadratic (rather than ap-
proximately cubic) relationship with height in men and women.2– 4
In the enlarged heart, wall (fibre) stress increases with LV size
(radius and volume). This increase is compensated by a proportional
increase of wall thickness, so that wall stress remains matched
with the systolic pressure. The ‘relative’ geometry of the ventricle
appears to be similar across species and body size, with normal
relative wall thickness [RWT, the ratio of twice the posterior wall
thickness (PW) and the LV diastolic diameter] from 0.32 to 0.42.5
Mass/volume ratios corresponding to the above-mentioned normal
RWTs range between 1.1 and 1.3.5 RWT and M/V do not require
correction for body size.
Effect of gender
Data fromseveral studies indicate that after adjustment for bloodpres-
sure and anthropometric parameters, LV volume and LVM are higher
in men than in women.6–8 These differences persist when values of
LVM are corrected for fat-free mass.9 This sex difference may
explain the surprising lack of consensus in appropriate indexation of
LVM, as it impacts the optimal method for indexing LVM for body
height. Figure 1 displays LVM, calculated by the Devereux formula
(unidimensional 2D measurements) in the healthy reference subgroup
of the Asklepios population.3 Using the allometric index 1.7, the body
Figure 1 Relationship between body height and LVM, calculated
by the Devereux formula (unidimensional 2D measurements).
Body height–LVM relationship in Asklepios reference participants
assessed with nonlinear regression with and without accounting
for the confounding effect of sex. The red line represents the
body height–LVM relationship in men. The blue line represents
the body height–LVM relationship in women. The black line repre-
sents the exaggeration of nonlinearity in the height–LVM relation-
ship when the confounding effect of sex is neglected.3 This
particularly leads to estimation problems at the extremes.
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height– LVMrelationship inmen(red)andwomen(blue) isparallel and
indexation for body height is optimally achieved by height (ht)1.7 in
both sexes.3,10 However, when an allometric exponent is computed
for males and females considered together (thick black line) without
adjustment for gender, there is an exaggeration of nonlinearity in the
height–LVM relationship (allometric index 2.7). This has important
clinical and epidemiological implications, resulting in marked overesti-
mation of the prevalence of LV hypertrophy in short subjects and a
marked underestimation in tall subjects. The appropriate indexation
remains an issue of contention.11
Effect of age
LV volumes are inversely associated with age. LVM decreases with age
as well, albeit to a more limited extent than volume. As a consequence,
RWT and M/V ratios increase. There is an age-related development
of a concentric remodelling (see the Identification of LV Geometric
Patterns section) with systolic and diastolic dysfunction.6,7,12
Effect of exercise and sport
Isotonic exercise involves movement of large muscle groups. The
profound vasodilatation of the skeletal muscle vasculature that is
involved produces hypertrophy by increasing venous return to the
heart and volume overload.13 This hypertrophy is characterized by
chamber enlargement and a proportional change in wall thickness,
with no changes in RWT. In contrast, isometric or static exercise
involves developing muscular tension against resistance with little
movement. Reflex and mechanical changes cause a pressure load
on the heart rather than a volume load resulting in a slightly enlarged
ventricle with increased RWT hypertrophy.13
Effect of obesity and diabetes
Obesity is associated with increased LV volumes, increased LVM, and
most typically increased RWT.6,14,15 In the Framingham study, an in-
crease of body mass index over time was closely related to increased
LVM and volumes.16 Insulin resistance, metabolic syndrome, and
diabetes mellitus type II are similarly associated with increased
LVM, RWT, and diastolic dysfunction.6,17,18 Diabetes patients have
decreased systolic function as well.17– 19 Correction of LVM for
height preserves both the effects of obesity and elevated blood
pressures on LVM. In contrast, correction of LVM for body surface
area (BSA) effectively corrects for not only height but also
obesity-related LV hypertrophy, which will remain undetected.3,15
Inherited and ethnic contributions
Some of the variance in LV dimensions and mass may be explained
by heredity, independent of the effects of sex, age, body size, blood
pressure, heart rate, medications, and diabetes.20 Familial patterns
of LV geometry were observed in subsequent generations of the
Framingham study, but not in spouses.21 The greatest inheritable
risk was found for concentric remodelling.
Normal ranges of LVM differ across races, being larger in African-
Americans than in white Americans and/or Hispanics and smaller
in Asian-Americans.3,7 Within one ethnicity, differences also exist
between populations, e.g. Scandinavians being different from Medi-
terraneans. Only a part of these differences is accountable to
ethnic variation in body size, and can be corrected by scaling.22 It is
still unclear to what extent ethnic differences prevail when scaling
for fat-free mass. It remains to be clarified to what extent these
ethnic and population differences include a different prognosis
and how to integrate ethnicities and populations in the definition of
hypertrophy. At present, normal values and cutoffs should be
adapted for each population.
LV hypertrophy due to increased load
Two basic patterns of cardiac hypertrophy occur in response to
haemodynamic overload.23 In pressure overload (e.g. hypertension),
pressure elevation most commonly leads to an increase in wall thick-
ness and RWT, a phenomenon known as concentric remodelling
(see the Identification of LV Geometric Patterns section). Eventually,
an increase in systolic wall stress leads to concentric hypertrophy,
caused by the addition of sarcomeres in parallel (hence, widening
the cardiac myocytes), an increase in myocyte cross-sectional area,
and an increase in LV wall thickening. In the Framingham Heart
study, hypertensive patients had a greater increase in LVM and
volume, and a smaller age-related reduction in LV size than individuals
with normal blood pressure.16 In contrast, eccentric hypertrophy
due to volume overload (e.g. with mitral regurgitation) is caused by
increased diastolic wall stress. This leads to an increase in myocyte
length with the addition of sarcomeres in series (hence, lengthening
of cardiac myocytes), thereby engendering LV enlargement.
Adaptation of LV function to increased
load
The complex changes that occur in the heart during LV remodelling
cause alterations in LV size and geometry, but the process of LV
remodelling also leads to alterations in contraction and relaxation,
the volume of myocyte and non-myocyte components of the myo-
cardium, the properties of the myocyte (sarcomeres, e.g. titin), and
the extracellular matrix (balance of collagen types I and III, and colla-
gen fraction). Diastolic function is influenced by alterations in LV
systolic function and geometry, delayed myocardial relaxation,
increased passive stiffness of the sarcomere and extracellular
matrix, and altered myocardial tone.24
Cardiac myocyte hypertrophy leads to foetal gene reactivation and
decreased expression of a number of genes normally expressed in
the adult heart. Depending on age, sex, duration of hypertension,
severity, and treatment, differing cellular and molecular events may
underlie the evolution from a ventricle with concentric hypertrophy
to a more dilated failing ventricle (often presenting as HFrEF, heart
failure reduced ejection fraction) or to a heavily fibrotic and non-
dilated ventricle (presenting as HFpEF, heart failure preserved
ejection fraction), according to the three stages in the hypertrophic
process (overload, hypertrophy, and failure).25 Physiological hyper-
trophy (growth, pregnancy, and exercise) is characterized by
normal organization of cardiac structure and normal or enhanced
cardiac function, whereas pathological hypertrophy is commonly
associated with upregulation of foetal genes, fibrosis, cardiac dysfunc-
tion, and increased mortality.13 The continuous vs. intermittent
nature of overload in the settings of pathological and physiological
hypertrophy is unlikely to account for the differences in response.13
In contrast to early-systolic load, late-systolic load delays myocardial
relaxation26,27 and induces more maladaptive hypertrophy.28
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Morphology of the hypertensive heart
LV morphology
LV hypertrophy is defined on a normative basis; a definition based on
2 SD above the mean LVM in the general population will differ from
a definition based on the healthy population without obesity or
hypertension.3 Separate cutoffs are required for men and women.
If LVM is corrected for BSA, it should be recognized that this corrects
for obesity-related LVM, or for height. In the end-stage hypertensive
heart, there is an increase in LV volumes and sphericity, a decrease in
stroke volume, and finally a reduction in EF.
LA morphology
Left atrial (LA) volume may be calculated by either area-length or
modified Simpson’s methods, and is usually scaled for BSA and
expressed in mL/m2; the normal range is up to and including
34 mL/m2.29 As with the LV, scaling by BSA corrects for an
obesity-related increase in LA size that as a consequence will remain
undetected. The LA is not symmetrical, and enlargement may occur
non-uniformly, predominantly in one direction. Consequently, LA
size is much better evaluated with 2D- or 3D-based LA volume
rather than with M-mode.30 In hypertension and other situations
where diastolic dysfunction occurs, reduction in early diastolic empty-
ing is compensated by forceful atrial contraction. In addition, intermit-
tentorpermanentelevationofLVfillingpressures leadstooverfillingof
the LA. The resulting LA enlargement is the ‘morpho-physiologic ex-
pression’ of chronic diastolic dysfunction, hypothesized to reflect the
durationand severityof increased LApressure. Although the presence
of atrial fibrillation itself contributes to atrial size, LA enlargement is
a well-known independent determinant of stroke, cardiovascular
events, and death.31 Moreover, atrial fibrosis may be anotherendpoint
of this process, predisposing to atrial remodelling and dysfunction with
atrial fibrillation. This is a common endpoint that may be initiated by a
number of aetiologies, including hypertension and diabetes mellitus.
The main determinants of an increasing atrial size with age are
the cardiovascular risk factors of elevated blood pressure and
obesity.31 In hypertensive patients, LA enlargement is related to
LVM (rather than the type of LV hypertrophy), overweight, higher
fasting glucose, and metabolic syndrome.32
Measurement of LVM
Linear echocardiographic dimensions
Acquisition and measurements
The measurement of LVM requires accurate measurements of wall
thickness and chamber dimensions, as described in the Chamber
Quantification update.29 The linear measurements of LV internal
dimension (LVDd), septal (IVS), and PW are made from the paraster-
nal long-axis acoustic window at the level of the LV minor axis,
approximately at the mitral valve leaflet tips. M-mode recordings
have excellent temporal resolution, and may be chosen from 2D
images. However, even when directed by 2D guidance, it may not
be possible to align the M-mode cursor perpendicular to the long
axis of the ventricle (Figure 2). Software has been developed to
Figure2 The importanceofon-axis imaging. Image showsalignmentof theM-modecursorperpendicular to the longaxisof theventricle.Orientation
A is orthogonal to the LV long axis, but lacks an imaging window (the beam would have to pass through the sternum). Orientation B is tangential to the
desired orthogonal LV axis and is unacceptable. If another window cannot be found, anatomical M-mode or direct 2D measurement may be required.
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 by guest on M
ay 25, 2015
http://ehjcimaging.oxfordjournals.org/
D
ow
nloaded from
 
reconstruct anatomical M-mode images from 2D images (Figure 3),
but this is not yet universally available. Reference normal values for
LV linear measurements are published in the Chamber Quantifica-
tion update.29 Alternatively, chamber dimension and wall thicknesses
can be acquired from the parasternal short-axis view using direct 2D
measurements. The use of 2D-derived linear dimensions overcomes
the common problem of oblique parasternal images resulting in over-
estimation of cavity and wall dimensions from M-mode (Figure 4).
When 2D measurements are used, the wall thicknesses and linear
dimensions should be measured at the level of the LV minor dimen-
sion, at the mitral leaflet tips level. The upper limit of normal for LVDd
is smaller than the M-mode measurement. Left ventricle internal di-
mension diastole (LVIDd), inter-ventricular septum diastole (IVSd),
and posterior wall diastole (PWd) are measured at end-diastole
from 2D or M-mode recordings, preferably on several beats.
Understanding the LVM literature is facilitated by recognizing
various methods:
(i) The original American Society of Echocardiography (ASE)
approach recommended that dimensions be measured from
the leading edge to the leading edge of echocardiographic
borders. This results in the inclusion of endocardial echoes
from the IVS and PW, and the exclusion of endocardial
echoes from the LVDd.33 This was because the trailing edge
of endocardial signals is dependent on gain settings. This may
impact on LVM measurements, especially at the upper and
lower extremes of these measurements.34 The simplified calc-
ulation of LVM with this approach is LVM ¼ 1.04[(IVS +
LVDd + PW)3 2 (LVDd)3] + 0.6 g.
(ii) The subsequent Penn convention excluded endocardial echoes
from IVS and PW dimensions, but included endocardial echoes
in measurement of the LVDd.35 As the Penn convention gives
larger cavity dimensions and smaller wall thicknesses than the
ASE convention, the use of this approach necessitates subtrac-
tion of 13.6 from the previous mass calculation.
(iii) The current ASE/European Association of Cardiovascular
Imaging (EACVI) Chamber Quantitation Guidelines point out
that refinements in image processing have allowed measure-
ment of the actual visualized thickness of the ventricular
septum and other chamber dimensions as defined by the
actual tissue–blood interface, rather than the distance
between the leading edge echoes, which had previously been
recommended (Figure 5).29
All LVM algorithms (M-mode, 2D, or 3D echocardiographic
measurements) are based on subtraction of the LV cavity volume
Figure 3 Reconstruction of anatomical M-mode images from 2D images. Overestimation of LV dimensions can occur through tangential imaging
at an angle to the appropriate axis (A). When the echo window cannot be moved, an alternative means of obtaining accurate data may be provided by
reconstructing the M-mode dataset from the 2D image—so-called anatomical M-mode (B). In this example, a small (1 mm) difference in LV dimen-
sion results in a 5 g difference in LVM. Tangential imaging may not just relate to selection of a longer than expected cross-section—it may under-
estimate the measurement by failure of the beam to pass through the axis of the ventricle (C). Again, the use of anatomical M-mode imaging may
circumvent this problem (D).
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fromthe volume enclosed by the LVepicardium to obtain the volume
of the shell between the LV cavity and the epicardial surface. This shell
volume is then converted to mass by multiplying LV wall volume by
the specific gravity of myocardium (1.05 g/mL). The formula used
for estimation of LVM from LV linear dimensions is based on model-
ling the LV as a prolate ellipse, and assumes that the major/minor
axis ratio is 2 : 1: LVM ¼ 0.8 × {1.04[(LVIDd + PW + IVSd)3 2
(LVIDd)3]} + 0.6 g. Extensive validation of this formula has been
performed from necropsy specimens.36
Normal values
Table 1 summarizes the reported range of normal values for LVM by
M-mode echocardiography.3,37– 45 These values differ between men
and women, with the latter systematically lower than the former,
even when indexed for BSA (Table 1; see the section below—
methods of indexation). The upper limits of normal ranges in the
ASE chamber quantification update are .95 g/m2 (.44 g/ht2.7) in
women and .115 g/m2 (.48 g/ht2.7) in men.29
Limitations
There are four principal limitations in the calculation of LVM using
linear methods:
(i) The ‘Cube’ formula is not accurate in patients with major distor-
tions of LV geometry (e.g. apical aneurysm, or any condition
where the 2 : 1 axis ratio requirement is not met).
(ii) Because this formula involves cubing primary measurements,
even small errors in these measurements may be magnified.
(iii) These measurements are insensitive to small changes in mass.
(iv) The measurements are highly dependent on imaging quality and
observer expertise.
Two-dimensional echocardiography
The most commonly used 2D methods for measuring LVM are
based on the area-length formula and the truncated ellipsoid
Figure 4 Use of 2D images for diastolic and systolic measure-
ments aligned orthogonal to the ventricular long axis at the junction
of chordae and mitral leaflets.
Figure 5 Range of measurement options for measuring LVM.
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model, as described in detail in the previous ASE/EACVI chamber
quantification document46 (Figure 6). In the presence of shape dis-
tortions, such as that caused by post-myocardial infarction (MI) re-
modelling, the geometric assumptions inherent in this approach
remain problematic. Both methods were validated in the early
1980s in animal models and by comparing premorbid echocardio-
grams with measured LV weight at autopsy in human beings.
Normal values are summarized in Table 2,47,48 and the degrees of
abnormality are classified in Table 3. The main limitations relate
to image quality and the temporal resolution of 2D imaging, com-
pared with M-mode echocardiography. The limitations of M-mode
regarding geometrical assumptions and the impact of small error
on measurements are also applicable to 2D measurements. In add-
ition, 2D imaging leads to frequent foreshortening due to inappropri-
ate cut-planes.
Three-dimensional echocardiography
The benefit of three-dimensional echocardiography (3DE) is espe-
cially to obviate inaccurate geometric assumptions, inherent to
2DE, that become exaggerated in remodelled ventricles. 3DE is a po-
tentially attractive modality for the measurement of LVM, and normal
ranges have been developed.49 The accuracy of 3DE is reportedly
similar to cardiac magnetic resonance (CMR) imaging methods for
measuring LVM.50– 52 However, there are wide limits of agreement
which primarily relate to difficulties in accurately tracing the LV
epicardial border, particularly in dilated ventricles,53 and generally
show that while 3DE is imperfect for LVM estimation—with a ten-
dency tounderestimateLVMcomparedwith CMR imaging in patients
with cardiac disease—the accuracy is more favourable than with
alternative ultrasound methods. Normal values of M-mode, 2D
mass, and 3D mass are given in Tables 1 and2. Degrees of abnormality
of LVM are summarized in Table 3 and the validation of all methods
against reference techniques is summarized in Table 4. A later
section describes the use of 2D and 3D for the assessment of LV
function.
Recommendations
LVM is prognostically important and should be reported in hypertensive
patients.
In the normally shaped LV, either M-mode or 2DE formulas can be used
to calculate LVM. The majority of community-acquired prognostic
evidence has been gathered with M-mode imaging.
In laboratories that use 3DE routinely, 3D LVM measurement should be
considered—especially in abnormally shaped ventricles or in
individuals with asymmetric or localized hypertrophy. 3DE is the only
echocardiographic technique that measures myocardial volume
directly, without geometric assumptions about LV shape and
distribution of wall thickening.
Identification of LV geometric
patterns
While patients with early hypertensive disease will most likely have
normal LV geometry,54 longstanding or untreated hypertension will
result in changes inLVshapeandeventually, a deteriorationof systolic
function. Broadly, the changes in LV geometry can be classified
according to whether LVM is normal or increased and whether ven-
tricular morphology (RWT) is altered46 (Table 5). RWT is variably
reported as (PW * 2)/LVd or (IVS + PW)/LVd, of which we favour
the former because septal measurements may be confounded by
the presence of septal bulge. RWT is problematic and not reflective
of true LV geometry in patients with asymmetric hypertrophy. The
upper limit of normal RWT is 0.42.29
Concentric LV hypertrophy
Concentric LV hypertrophy, probably most commonly associated
with hypertension, is characterized by normal cavity size, uniformly
increased LV wall thickness, and increased LVM (Figures 7 and 8).46
Cutoff values adopted by the ASE and EACVI are based on either
overall LVM (g), LVM /BSA (g/m2), LVM/height (g/m), or LVM/
height2.7 (g/m2.7) and while each has been shown to have limitations
of either under- or overestimating LVM, each has been used success-
fully in characterizing LV hypertrophy in different patient populations.
Concentric LV hypertrophy is an adaptive response to high sys-
temic pressure caused by hypertension or diseases such as aortic
stenosis, coupled with high peripheral resistance. Concentric LV
hypertrophy (LVH) and changes in LV geometry have been shown
to affect both men and women regardless of age,55 and are also asso-
ciated with changes in diastolic function, longitudinal and radial myo-
cardial function, and atrial size.56– 58
Eccentric LV hypertrophy
In contrast to concentric LVH, eccentric hypertrophy is associated
with volume, rather than pressure overload. This is usually due to
significant valvular regurgitation or high cardiac index, as is seen
in elite athletes (although concentric hypertrophy may be the con-
sequence of strength training). Systemic pressure is normal and per-
ipheral resistance is not increased in patients with eccentric
hypertrophy. Echocardiographic findings show increased LV cavity
size, normal LV wall thickness, and increased LVM (Figure 9).
Patients with eccentric hypertrophy share similar changes in dia-
stolic function and longitudinal and radial function as those
with concentric hypertrophy.55,57,58 Unlike concentric hyper-
trophy, however, patients with eccentric LVH generally have low
normal or mildly impaired systolic function due to chronic volume
overload.
Changes in LV shape associated with LV enlargement have been
quantified as sphericity index. This is a ratio between measured
end diastolic volume (EDV) (preferably with 3DE) and a spherical
volume based on the longitudinal dimension of the LV (4/3 × p ×
D/2).2 This parameter has been shown to be a predictor of remodel-
ling, but this is more in the setting of LV dysfunction after MI than in
hypertensive heart disease.59
Concentric remodelling
Concentric LV remodelling is a late stage response of the LV and can
be caused by chronic pressure, volume overload, or MI. It is most
commonly associated with coronary artery disease, but is also asso-
ciated with longstanding hypertension, especially untreated hyper-
tension.60 Like eccentric hypertrophy, it is also associated with LV
systolic dysfunction. Echocardiographic features show normal or
small LV cavity size, usually increased LV wall thickness and normal
Recommendations on the use of echocardiography in adult hypertension 583
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Table 1 Normal limits of M-mode LVM
Source Year Men Women Age
(years)
Body size
indexation
Measurement
convention
LVM Upper limit of LVMI Basis for upper limits
Men Women Men Women
Henry et al.37 1980 78 58 20–97 None ASE 160+25 * g (107+17 g/m2) 210 * g (140 g/m2) 95% CL
Devereux et al.38 1981 106 120 39+13 BSA Penn 89+21 69+19 136 g/m2 112 g/m2 97th percentile
Hammond et al.39 1984 83 77 44+13 BSA Penn 155+50 g (Penn)
193+55 g (ASE)
84+23 g/m2
(Penn)
– 134 g/m 110 g/m2 Comparison with hypertensive
population: LV determination
Byrd et al.40 1985 44 40 35+10 BSA – 148+26 g
76+13 g/m2
108+21 g
66+11 g/m2
200 g
102 g/m2
150 g
88 g/m2
95th percentile
Levy et al.41 1987 347 50 43+12 Ht/BSA ASE 208+43 g (ASE)
177+41 g (Penn)
145+27 g
(ASE)
118+24 g
(Penn)
294 g
163 g/m
150 g/m2
198 g
121 g/m
120 g/m2
M + 2 SD
Koren et al.42 1991 167 86 47+13 BSA Penn – – 125 g/m2 125 g/m2 CV risk at 10 years
de Simone et al.43 1992 137 91 39+14 None
Height
Height2.7
BSA
Penn
Penn
Penn
Penn
155+34 g
89+19 g/m
35+8 g/m2.7
89+16 g/m2
117+28 g
72+17 g/m2.7
32+8 g/m2
73+16 g/m2
223 g
127 g/m2.7
51 g/m2
117 g/m2
173 g
106 g/m2
48 g/m2
105 g/m2
M + 2 SD
M + 2 SD
M + 2 SD
M + 2 SD
Kuch et al.44 2000 213 291 42+12 Height
Height2.7
BSA
FFM
ASE
ASE
ASE
ASE
97+21 g/m
37+8 g/m2.7
89+18 g/m2
2.91+0.59 g/kg
71+18 g/m
31+8 g/m2.7
70+17 g/m2
2.71+0.70 g/
kg
139 g/m
53 g/m2.7
135 g/m2
4.09 g/kg
107 g/m
47 g/m2.7
104 g/m2
4.11 g/kg
M + 2 SD
M + 2 SD
M + 2 SD
M + 2 SD
CV Health Study45 2001 651 1066 72+5
(65–98)
None
Height
Height2.7
BSA
ASE
ASE
ASE
ASE
166+45 g
96+27 g/m
37+11 g/m2.7
87+24 g/m2
127+35 g
80+22 g/m
36+10 g/m2.7
77+19 g/m2
256 g
150 g/m
59 g/m2.7
135 g/m2
197 g
124 g/m
56 g/m2.7
115 g/m2
M + 2 SD
M + 2 SD
M + 2 SD
M + 2 SD
CV Health Study
(Healthy Substudy)
2013 93 213 75+4 None
Height
Height2.7
BSA
ASE
ASE
ASE
ASE
146+36 g
84+20 g/m
33+9 g/m2.7
77+19 g/m2
121+32 g
76+20 g/m
34+9 g/m2.7
74+19 g/m2
218 g
124 g/m
51 g/m2.7
115 g/m2
185 g
116 g/m
52 g/m2.7
114 g/m2
M + 2 SD
M + 2 SD
M + 2 SD
M + 2 SD
Asklepios—total
population3
2007 1301 1223 46 (41–51)
(35–55)
None
Height1.7
BSA
2D
2D
2D
175+39 g
67+15 g/m1.7
87+17 g/m2
121+30 g
53+13 g/m1.7
69+14 g/m2
243 g
92 g/m1.7
116 g/m2
177 g
77 g/m1.7
94 g/m2
95th percentile
95th percentile
95th percentile
Asklepios Healthy, Risk
factor deprived3
2007 198 414 43 (39–48)
(35–55)
None
Height1.7
BSA
2D
2D
2D
155+36 g
58+13 g/m1.7
82+17 g/m2
108+21 g
46+9 g/m1.7
65+11 g/m2
214 g
81 g/m1.7
112 g/m2
143 g
60 g/m1.7
86 g/m2
95th percentile
95th percentile
95th percentile
CHS healthy subgroup: no prevalent HF, CVD, hypertension, obesity, or subclinical heart disease (i.e. normal aortic augmentation index and normal carotid intima-media thickness).
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LVM (Figures 7 and 10). Concentric remodelling is also associated
with changes in the shape of the LV—e.g. LV sphericity changes—
and becomes more rounded, rather than bullet shape.1 The result
of this is more dramatic degradation of diastolic function and loss
of radial and longitudinal function.57
Other classification
The limitation of the classical categories is the suboptimal categoriza-
tion of dilated ventricles.61 Recently, Gaasch and Zile5 proposed a
subdivision based on LVM (vertical axis), LV volume (horizontal
axis), and RWT or M/V, represented by the oblique lines indicating
the upper (full) and lower (dashed) limit of normality (Table 6 and
Figure 7). Using this approach, the non-dilated ventricle is character-
ized as having normal morphology, concentric remodelling, or
concentric hypertrophy, based on LVH and RWT (.0.42). Dilated
ventricles without LVHare described as having eccentric remodelling
if the RWT is ,0.32. Dilated ventricles with LVH are described as
having eccentric hypertrophy (RWT ,0.32), mixed hypertrophy
(RWT .0.42), or physiological hypertrophy (RWT 0.32–0.42).
The resulting categories yield distinct functional behaviours and
prognoses.
Natural history of LV geometry
in hypertension
Left ventricular hypertrophy is caused by increased wall stress, either
due to chronic pressure overload, as seen in hypertension, or the
volume overload seen in valvular disease. However, in early, mild
hypertension, LVH is usually absent and the first manifestation of
Figure 6 Estimation of LVM using 2D echo techniques. 2D LVM calculation based on area-length (AL) and truncated ellipsoid (TE) formulae,
obtained from short-axis and apical four-chamber views. A1: total LV area; A2: LV cavity area; Am: the myocardial area. LV long- and short-axes
are given by a and b, with d representing the truncated long axis from the widest short axis to the mitral plane.
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Table 2 Normal values (mean+ SD) for LVM by 2D and 3D echo29,48,49
European Japanese
Men Women Men Women
2D LVM (g) 96–200 66–150
2D LVM index (g/m2) 50–102 44–88
3D LVM (g)
3D LVM index (g/m2) 77 (57–97) 74 (58–90) 64 (40–88) 56 (34–78)
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hypertension is diastolic dysfunction.58,62 This can be detected as
grade 1 diastolic impairment, or impaired relaxation. Over time
however, if left untreated, filling pressures continue to rise, ventri-
cular hypertrophy develops as an adaptive response to chronic
pressure, and more severe disturbances of diastolic filling are more
commonly encountered. Eventually, LV remodelling will occur and
left ventricular systolic function will become impaired. While the
goal of hypertension management is to prevent any changes in LV
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Table 3 Degrees of abnormality of LVM
Women Men
Reference
range
Mildly
abnormal
Moderately
abnormal
Severely
abnormal
Reference
Range
Mildly
abnormal
Moderately
abnormal
Severely
abnormal
Linear method
LVM, g 67–162 163–186 187–210 ≥211 88–224 225–258 259–292 ≥293
LVM/BSA, g/m2 43–95 96–108 109–121 ≥122 49–115 116–131 132–148 ≥149
LVM/height, g/m 41–99 100–115 116–128 ≥129 52–126 127–144 145–162 ≥163
LVM /height2.7, g/m2.7 18–44 45–51 52–58 ≥59 20–48 49–55 56–63 ≥64
Relative wall thickness, cm 0.22–0.42 0.43–0.47 0.48–0.52 ≥0.53 0.24–0.42 0.43–0.46 0.47–0.51 ≥0.52
Septal thickness, cm 0.6–0.9 1.0–1.2 1.3–1.5 ≥1.6 0.6–1.0 1.1–1.3 1.4–1.6 ≥1.7
Posterior wall thickness, cm 0.6–0.9 1.0–1.2 1.3–1.5 ≥1.6 0.6–1.0 1.1–1.3 1.4–1.6 ≥1.7
2D method
LVM, g 66–150 151–171 172–182 .193 96–200 201–227 228–254 .255
LVM/BSA, g/m2 44–88 89–100 101–112 ≥113 50–102 103–116 117–130 ≥131
BSA, body surface area; LV, left ventricular; 2D, two-dimensional.
Bold italic values: recommended and best validated.
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Table 4 Correlation of all echocardiographic methods of LVM calculation vs. MRI
End-diastole End-systole
r SEE (g) P-value Regression equation r SEE (g) P-value Regression equation
1D Echo-Penn vs. CMR 0.725 25.6 0.018 1D Echo-Penn ¼ 0.99
(CMR) + 4.0
0.788 28.7 0.007 1D Echo-Penn ¼ 1.35
(CMR)2 19.2
2D Echo-AL vs. CMR 0.694 24.2 0.030 2D Echo-AL ¼ 0.86
CMR) + 32.4
0.717 28.2 0.030 2D Echo-AL ¼ 1.10
(CMR) + 14.1
2D Echo-TE vs. CMR 0.687 21.8 0.030 2D Echo-TE ¼ 0.76
(CMR) + 27.7
0.710 24.5 0.020 2D Echo-TE ¼ 0.90
(CMR) + 13.0
3D Echo-PSR vs. CMR 0.882 10.4 0.001 3D Echo-PSR ¼ 0.72
(CMR) + 32.2
0.908 10.8 0.001 3D Echo-PSR ¼ 0.86
(CMR) + 13.2
CMR, magnetic resonance imaging; 1D Echo-Penn, M-mode echocardiographic method (Penn convention); 2D Echo-AL, two-dimensional echocardiographic area-length method;
2D Echo-TE, two-dimensional echocardiographic truncated ellipsoid method (8); 3D Echo-PSR, three-dimensional echocardiographic polyhedral surface reconstruction method.
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Table 5 Classical description of LV geometry
LV geometry LVM RWT
Normal ≤115 g/m2 (men) or ≤95 g/m2 (women) ,0.42
Concentric hypertrophy .115 g/m2 (men) or .95 g/m2 (women) .0.42
Eccentric hypertrophy .115 g/m2 (men) or .95 g/m2 (women) ,0.42
Concentric remodelling ≤115 g/m2 (men) or ≤95 g/m2 (women) .0.42
Measurements performed using 2D-directed M-mode.29
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geometry, the current ability of echocardiography to provide serial
assessment of the LV response in the individual patient is compro-
mised by variability of LVM measurement.
Recommendations
Description of LV geometry, using at the minimum the four categoriesof
normal geometry, concentric remodelling, and concentric and
eccentric hypertrophy, should be a standard component of the
echocardiography report.
Tissue characterization
The haemodynamic disturbances and humoral stimulation that lead
to the cardiac responses to hypertension63 do not necessarily pro-
gress in parallel.64 While measurement of LVM addresses the re-
sponse to haemodynamic disturbance, this may not necessarily
reflect the full physiological impact of hypertension on the heart.
While not part of current guidelines, tissue characterization may
provide information about myocardial remodelling, and allow tar-
geted therapy against molecular changes, sarcoplasmic failure, apop-
tosis, fibrosis, and disturbances of vascular structure and function.65
Interstitial, perivascular, plexiform, and replacement fibrosis of nec-
rotic tissue66 are likely responsible for disturbances of myocardial
perfusion, synchrony, and rhythm.
An important reason for attempting to characterize myocardial
tissue is that not all increments in LVM that occur in the setting of
hypertensive heart disease are due to hypertension. The recognition
of other causes of increased wall thickness, including athletic hyper-
trophy, valvular disease, infiltrative disorders (amyloid, Friedrich’s
ataxia, and Fabry’s disease), non-compaction, and hypertrophic car-
diomyopathy,67 has important treatment implications.
Tests of myocardial tissue characterization can be divided into
processes that measure tissue reflection (and therefore tissue
density), and functional changes that are due to the dynamic conse-
quences of changes in myocardial ultrastructure (which are discussed
in the section on LV function). The only echocardiographic marker of
tissue density is integrated backscatter, a measure of ultrasonic
scatter from small reflectors, which relate to tissue density.68 Cali-
brated integrated backscatter refers to a method whereby the amp-
litude of reflection is measured in relation to the amplitude deriving
froma reference tissue, forexample, bloodwithin the LV cavityor the
pericardium. The primary determinant of both scatter and attenu-
ation in myocardial tissue is collagen.69 However, as scatter is also
related to position and orientation of myofibrils relative to the ultra-
sound beam, variations in these measurements are not specific for
Figure 7 LV geometric patterns classified according to LVM, LV
volume, and RWT. The red horizontal line separates LVH from
normal LVM. The black vertical line separates dilated from non-
dilated ventricles. The two oblique blue lines delimit the upper
(0.42) and lower (0.32) limit of normal RWT. This leads to eight cat-
egories of ventricles. The grey ellipse indicates the area of normal
ventricles including physiological LV enlargement.
Figure 8 Concentric LVH. Parasternal long-axis (left) and apical four-chamber views (right) from a 55-year-old hypertensive male patient with
concentric LVH. LVDd 48 mm; LVDs 34 mm; IVS 18 mm; PW 15 mm; EF 60%; LVM 268 g.
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Figure 9 Eccentric LVH. Parasternal long-axis view (left) and apical four-chamber view (right) of a 28-year-old female patient with a failed mitral
valve repair showing eccentric LVH. LVDd 56 mm; LVDs 39 mm; IVS 12 mm; PW 12 mm; EF 50%; LVM 206 g.
Figure 10 Concentric LV remodelling. A 59-year-old male patient with concentric LV remodelling. LVEDD 47 mm; LVESD 36 mm; IVS 20 mm;
PW 11 mm; EF 43%; LVM 270 g.
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Table6 Characterization of LV geometry based on LVM (vertical axis), LV volume (horizontal axis), and RWT, measured
using 2D-directed M-mode29
LV geometric pattern LV volume index (mL/m2) LVM index (g/m2) RWT
Normal ventricle ≤75 ≤115 (men) or ≤95 (women) 0.32–0.42
Physiological hypertrophy .75 .115 (men) or .95 (women) 0.32–0.42
Concentric remodelling ≤75 ≤115 (men) or ≤95 (women) .0.42
Eccentric remodelling .75 ≤115 (men) or ≤95 (women) ,0.32
Concentric hypertrophy ≤75 .115 (men) or .95 (women) .0.42
Mixed hypertrophy .75 .115 (men) or .95 (women) .0.42
Dilated hypertrophy .75 .115 (men) or .95 (women) 0.32–0.42
Eccentric hypertrophy .75 .115 (men) or .95 (women) ,0.32
T.H. Marwick et al.588
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fibrosis and backscatter and attenuation is also affected by angle of
insonation (i.e. the same myocardial segment will have different ultra-
sound characteristics when viewed from orthogonal windows—
parasternal long axis vs. apical) due to the alignment of myofibrils per-
pendicular or parallel to the ultrasound beam. Thus, feasibility can be
limited.70 Moreover, these changes in early hypertensive heart
disease may be subtle.71
Two other imaging methods are probably superior to echocardi-
ography for myocardial tissue characterization. Late gadolinium en-
hancement with CMR has become widely used for the recognition
of replacement fibrosis in ischaemic heart disease.72 The same has
also been helpful in understanding the contribution of fibrosis in
hypertrophy, where 50% of patients with hypertensive LVH mani-
fest patchy late enhancement,73 which correlates with the presence
of diastolic dysfunction.74 The problem with this technique is that it is
based on defining a reference normal segment within the myocar-
dium, so it may be misleading for the detection of diffuse interstitial
fibrosis. A potential solution is the use of T1 mapping, which allows
the recognition of differences in T1 relaxation between the normal
and fibrotic myocardium. Recent work has validated T1 mapping
as an accurate marker of the extent of diffuse fibrosis.75 The
final methods that are used in tissue characterization are ‘cardiac
nuclear imaging’ procedures for molecular imaging of collagen76
and detection of apoptosis.77
Other echocardiographic markers—for example tissue Doppler
and strain—have been used as markers of fibrosis.66 It should be
recognized that these functional parameters may be confounded
by myocardial processes that parallel the development of fibrosis,
and may not be optimal for this purpose.78
Recommendations
Myocardial characterization using CMR can identify non-hypertrophic
causes of LV thickening. It should be considered when (i) the degree
of LV thickening is at least moderate, (ii) severity of the LV thickening
is inconsistent with the severityof hypertension, (iii) there is evidence
of LV dysfunction despite appropriate BP control, (iv) other features
raise the prospect of an infiltrative process (severe thickening,
alteration of tissue density on fundamental imaging, or e′ velocity
,5 cm/s).
Arterial function and
ventriculo-arterial matching
Arterial function
Arterial afterload
Arterial afterload is characterized by both steady and pulsatile compo-
nents of blood pressure.79 This parameter is determined by imped-
ance, compliance, or resistance, derived from aortic pressure (Pao)
andflowwaveforms(Fao),bothofwhichcanbeassessednon-invasively
by means of applanation tonometry and ultrasound, respectively.
A variety of measurements have been created to better under-
stand the process of displacement of blood from the LV into the ar-
terial tree (Figure 11). If the arterial system was composed of rigid
tubes without any storage capacity, blood would be accelerated in
systole throughout the complete arterial tree, which would give
rise to very large intra-arterial pressure differences (and a high
load on the heart). Owing to the elasticity of the large arteries,
however, part of the stroke volume is locally stored in the aorta in
systole (the ‘windkessel’ function), buffering the pulsatility of blood
flow and providing a more continuous blood flow in the distal circu-
lation. This reduces the importance of inertial forces. Characteristic
impedance (Zc) reflects the interplay between these inertial effects
and the local storage of blood in the proximal aorta and the load ini-
tially experienced by the ventricle upon opening of the aortic valve. It
is calculated by plotting the relation of time-varying Pao (aortic pres-
sure) vs. time-varying Fao (aortic flow) during the ejection phase of
the cardiac cycle; the slope provides Zc [in mmHg/(mL/s)]. This par-
ameter is dependent on blood pressure and aortic size; a stiff and
narrow aorta leads to high Zc, a distensible, wide aorta to a low Zc.
While Zc determines the upstroke of pressure, pulse pressure is
mainly determined by the total arterial compliance (TAC) of the ar-
terial tree in combinationwith the systemicvascular resistance (SVR).
The simplest approximation of TAC is the ratio of the stroke volume
and pulse pressure (mL/mmHg), although this leads to systematic
overestimation. TAC is highly size-dependent, depends non-linearly
on arterial pressure, and that there are systematic differences
between different methods, making TAC a parameter difficult to
standardize (Figure 11).
Arterial afterload: pulse wave velocity and wave reflection
The above section simplifies the arterial system to a simple ‘windkes-
sel’ system. Cardiac contraction gives rise to pressure- and flow
waves travelling through the arterial tree. The stiffer the arteries,
the higher the pulse wave velocity (PWV; Figure 12). PWV is propor-
tional to the intrinsic mechanical properties of the arterial wall
(stress–strain relationships), the ratio of wall thickness to lumen
diameter, and inversely proportional to the density of blood
(which is virtually constant). Thus, PWV is independent of size
and only varies with arterial remodelling or changes in arterial
tissue properties (note that these are pressure-dependent). The
carotid and femoral artery is the most commonly used measuring
locations, with time delay derived from either pressure (tonometry),
ultrasound- (pulsed Doppler), or CMR-based (phase contrast)
signals. As the carotid and femoral artery is not along a single un-
equivocal trajectory, the latest consensus is that distance is approxi-
mated as 0.8 times the linear distance measured directly between the
carotid and femoral sites. Age-specific normal values for carotid–
femoral have been reported (Figure 13), but have the disadvantage
of obscuring the important effect of age.81 Numerous studies have
now demonstrated an association between increased arterial stiff-
ness and increased cardiovascular risk. Although PWV provides an
overall estimate of the elastic properties of the aorta and central ar-
teries, it alsodependson functional and dynamicproperties, including
production of nitric oxide. It is also possible to assess the local elastic
properties at the carotid or femoral artery, and several ultrasound-
based techniques exist for this purpose (e.g. wall tracking to
measure arterial distension) or are under investigation (pulse wave
imaging and shear wave imaging).
Wave dynamics are too complex to resolve in full detail in an in vivo
setting and are commonly simplified, considering only one forward
(generated by the heart) and one backward wave (due to reflections
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in the periphery). The timing and magnitude of these waves can dir-
ectly be linked to cardiovascular pathophysiology. Recent studies
have reported an association between augmentation index (a
rather poor measure of wave reflection) and cardiovascular risk,82 al-
though there is disagreement about the prognostic value of this infor-
mation. An increased magnitude of wave reflection, measured with
the wave decomposition technique, is an independent prognostic
determinant of cardiovascular risk and a powerful and independent
predictor of incident heart failure.83
Ventriculo-arterial interaction
The classical approach to ventriculo-arterial matching
The most widespread paradigm for the assessment of ventricular–
vascular coupling is the ventricular (Ees)–arterial (Ea) elastance
framework, which links mechanical performance of the ventricle to
its oxygen consumption.
Foran efficient energy transfer, the LV should develop an elastance
that is greater than the arterial elastance. Arterial elastance is com-
monly calculated as end-systolic pressure/stroke volume and is a
measure of resistive, not pulsatile load. Ees is the end-systolic
elastance (slope of the end-systolic pressure–volume relation), a
measure of ventricular contractility. Ea stands for arterial elastance
(ratio of end-systolic pressure and stroke volume), although it is an
imperfect measure of arterial properties, being highly sensitive to
the heart rate. Resting Ea/Ees ratios of 0.62–0.82 are observed
across species and in human populations. The LV generates maximal
stroke work when Ea/Ees ¼ 0.80, while it operates at maximal ener-
getic efficiency with an Ea/Ees of 0.70.84 The normal Ea/Ees values
seen in the Asklepios cohort85 and the Olmsted cohort86 suggest
that normal subjects’ Ea/Ees values approximate this optimal value.
Values .1 indicate an ‘ill-matched’ ventricle and arterial system.
While the framework is essentially based on pressure–volume loop
analysis—and hence restricted to an invasive setting—it has been
simplified tomake it suitable for application in clinical settings, approxi-
mating Ees as the ratio of end-systolic pressure and the end-systolic
volume (ESV) or via the useof single-beat methods that take advantage
of the relatively small variability in the shape of the normalized time-
varying left ventricular elastance curve over the cardiac cycle.87,88
Novel approaches to ventriculo-arterial matching
The standard Ea/Ees analysis does not involve any evaluation of time
in the analysis. Using cardiac ultrasound and applanation tonometry
(Figure 13), myocardial stress can be expressed as a function of time
Figure 11 Overview of all components of arterial afterload. The table summarizes the contributors to the haemodynamic parameters and the
schematic figure on the right emphasizes the roles of impedance and reflection. The graphic at the bottom left summarizes the assessment of
characteristic impedance from measured aortic pressure and flow waveforms. SVR: systemic vascular resistance; TAC: total arterial compliance.
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throughout systole.89 Peak stress occurs in early systole, before im-
portant contributions of reflected waves to central pressure and cor-
relates directly with SVR and Zc.80 The greater peak and end-systolic
wall stress and higher ejection phase stress-time integral in women
may relate to the susceptibility of women to heart failure.80
Wave intensity analysis is a new method of assessing ventriculo-
vascular interaction. There are three aortic waves: (i) a wave reflect-
ing LV contraction, generating a forward wave increasing pressure
and flow; (ii) a reflected wave, generally increasing pressure and low-
ering blood flow, and (iii) a late-systolic wave due to LV relaxation,
lowering blood pressure and flow. Current research is seeking
whether this wave-based analysis can be used to quantify cardiac
systolic and diastolic performance.
Assessment of the aorta
Hypertension is an important contributor to aortic disease, and any
echocardiogram performed for the evaluation of end-organ disease
should include assessment of the aorta. Echocardiographic views
are usually limited to the ascending aorta between the coronary
sinuses and main pulmonary artery, the aortic arch (in the supraster-
nal view), the descending aorta in the far-field of the parasternal,
suprasternal, and foreshortened apical two-chamber view, and the
abdominal aorta in the subcostal view. In particular, this simple step
adds an incremental value in screening men.65–70 years old for ab-
dominal aortic aneurysm, especially if they are smokers. Coarctation
of the aorta is a well-known structural abnormality that can lead to
hypertension and LV hypertrophy and may go undetected by clinical
assessment, particularly in younger adults. The echocardiogram is
central to making this diagnosis, so younger patients presenting
with hypertension should undergo 2D imaging, colour and Doppler
assessment of the distal arch and upper descending aorta. Further
information about echocardiography and aortic disease, including
normal aortic dimensions, are described in the EACVI recommenda-
tions for clinical practice.90
Recommendations
Blood pressure should be obtained at the time of the examination and
integrated into the report.
Aortic dimensions should be reported in all studies of hypertensive
subjects.
Measurement of pulse wave velocity should be considered as a marker
of vascular health and risk in primary prevention patients.
Assessment of ventriculo-arterial mismatch is currently a research
rather than a routine clinical investigation.
Figure 12 Measurement of carotid–femoral PWV, currently considered as a reference standard measure of arterial stiffness. The table displays
normal values of PWV as established by the Working Group on Arterial Stiffness.80
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LV systolic function in hypertension
Parameters from linear measurements
LV linear dimensions for the calculation of LVM are widely used in the
setting of hypertensive patients. The use of these measurements for
the evaluation of endocardial fractional shortening (FS) has been
superseded by more accurate and reliable measures. Likewise, the
Teichholz or Quinones methods for measurement of EF from
linear measurements are dependent on geometric assumptions and
are not recommended.
Two-dimensional measurements
While the process of tracing LVM (above) and volumes are similar, the
prognostic independence of LVM and function justifies their separ-
ation. The techniques and reference normal values for obtaining EF
from tomographic 2D echocardiography are summarized in the
ChamberQuantificationupdate.29 Thebiplanemethodofdiscs (modi-
fiedSimpson’s ruleobtained fromapical four-andtwo-chamberviews)
is the most accurate in abnormally shaped ventricles.46,91
In the pre-harmonic and pre-digital era, the main sources of inter-
study variability included repeated echo recordings, repeated video
measurements, and measurements made by different investigators.92
Similar analyses have not been performed by harmonic imaging,
which may be an important distinction for two reasons. The use of
lower frequencies (required for the creation of a wider broadband)
implies a reduction of spatial resolution, with apparently thicker
structures and potential effects on the measurement of wall
thickness. On the other hand, the use of harmonic imaging improves
the reproducibility of 2D LV volumes.93 When compared with CMR,
2D determination of LV volumes shows higher interstudy variability
which reaches statistical significance for LV ESV (4.4–9.2% vs. 13.7–
20.3%, P, 0.001),94 and results in higher calculated sample sizes
(increases of 55–93% in comparison with CMR) to show clinically
relevant changes in LV size.
The ejection phase indices (FS, EF, stroke volume, and cardiac
output) cannot determine the relative contribution of each of
these variables to LV pump function. In particular, load dependency
of these parameters may induce inaccurate estimation of intrinsic
myocardial contractility in chronic pressure overload conditions.
The estimation of LV afterload may help in determining whether or
notobservedLVpump function is representativeof actualmyocardial
contractile performance. The most direct measurement of LV after-
load is end-systolic stress (ESS).95 Two main types of ESS can be
measured, meridional and circumferential ESS (cESS), each acting
as counter forces to fibre shortening.95 Longitudinal shortening of
endocardial fibres is limited by longitudinal (meridional) ESS, which
can be measured using a catheterization-validated formula which
incorporates end-systolic LV internal diameter (LVIDs) and wall
thickness coupled with simultaneous cuff blood pressure.36
Three-dimensional measurements
Assessment of LV volumes by 2DE is limited by foreshortening, mal-
rotation, angulation, and a reliance on geometric assumptions for
volumetric calculation, resulting in an underestimation of the true
Figure 13 Assessment of time-varying myocardial stress using applanation tonometry and cardiac ultrasound. Myocardial stress peaks in early
systole. Late-systolic stress is significantly reduced due to the decrease in LV cavity volume throughout systole. The dotted line represents the
middle third of ejection.
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volumes, particularly in remodelled ventricles.96,97 Transthoracic
3DE provides a rapid and accurate method for quantifying LV
volumes and EF (LVEF).98,99 It has a superior reproducibility to
2DE, with a closer correlation to CMR-derived volumes.50,96 For
these reasons, the ASE and EACVI recently recommended 3DE,
rather than 2DE, for the routine assessment of LV volumes and EF.100
Two recent studies have addressed normal ranges of 3D measure-
ments but identified somewhat different normal values, emphasizing
racial, gender, and age differences.49,101
A recent meta-analysis of validation studies comparing 3DE and
CMR demonstrated that considerable variability still exists in the
measurement of LV volumes (+34 mL for EDV, +30 mL for ESV,
and +12% for EF), although it is less than that observed between
2DE and CMR.97 Moreover, both 2DE- and 3DE-derived volumes
are less accurate in dilated LVs.102 Several sources of 3D volume ac-
quisition and measurement error are discussed in the recent ASE/
EACVI guidelines, including difficulty in imaging the anterior and
lateral walls because of interference from ribs, low line density (and
therefore lower spatial resolution—which may be partly read-
dressed with the use of LV opacification), low temporal resolution
(which may be addressed by using multiple subvolumes—but at the
risk of stitching artefacts), and time-consuming off-line analysis.100
Recently, a fully automated endocardial contouring systemcombined
with real-time full-volume 3DE has been described as providing
accurate and reproducible volumes.103
Midwall function
Rationale
LV systolic function is commonly assessed through the use of EF and
FS. However, because these measurements are performed at the
endocardial surface, their appropriateness has been questioned in
patients with LV hypertrophy. The inner layer of the LV has been
shown to move inward further than the outer layer, a difference
markedly increased in hypertrophic walls due to the ‘cross-fibre
shortening’ phenomenon which, in hypertrophic LVs, achieves
normal systolic wall thickening despite reduced shortening of individ-
ual myocardial segments.104 –106 Hence, LVEF and FS often lead to
overestimation of LV systolic performance yielding normal or even
supranormal results not matching the individual’s clinical situation
and prognosis, since they take into account geometric changes that
do not accurately reflect the actual contractile function of the
myocardium.104,107 – 109 The greatest proportion of ventricular
myocardial fibres is located in the myocardial midwall, the region
responsible for circumferential left ventricular contraction and
where cross-fibre shortening is less significant.110– 112 Consequently,
indices representing LV midwall mechanics have received increasing
attention lately, as they have shown to better reflect myocardial con-
tractile status in patients with LV hypertrophy.109,113,114
A variety of parameters have been used to assess LV midwall func-
tion. Midwall FS (FSmw) has been the most widely used. Based on
M-mode measurements, calculation of FSmw is generally calculated
following the model described by Shimizu et al.,104,115 based on the
assumption of a cylindrical-shaped LV resulting from the union of
two concentric cylindrical shells of equal end-diastolic thickness
and on the fact that LVM does not vary throughout the cardiac
cycle. This model allowsFSmw to be calculated through the following
formula: FSmw ¼ {(LVIDd + IVSd/2 + PWd/2)2 (LVIDs + Hs/2)}/
LVDd + IVSd/2 + PWd/2), where Hs is the systolic thickness of
the shell. To eliminate the effects of LV afterload on FSmw, stress-
corrected FSmw is calculated through the following formula:
cESS¼ {[SBP× (LVIDs/2)2] × [1+ (LVIDs/2+ LV2 PWs)2/(LVIDs/
2 + LV2 PWs/2)2]}/{(LVIDs/2+ LV2 PWs)22 (LVIDs/2)2}, where
SBP represents systolic bloodpressure.109 This correctionhas shown
to discriminate hypertensive from physiological LV hypertrophy in
athletes.
Validation and normal values
Several studies have provided a reference of normal absolute and
stress-corrected FSmw values in healthy populations.109,116 –120
Mean normal values in these studies range from 17 to 21%, with no
observed differences with gender and ethnicity, and while most
studies have pointed out a slight decrease in FSmw with age, these
may be due to subclinical conditions and have shown no statistical sig-
nificance in some series in which the study population was screened
to rule out cardiovascular disease.119
The study of midwall mechanics has shown to be superior to other
conventional echocardiographic indices of LV systolic function in
several clinical scenarios, through better prediction of cardiovascular
outcomes than indices based on endocardial measurements and
better correlation with patients’ clinical status.120 – 123
Limitations
Some of the limitations of midwall function assessment include the
fact that FSmw is based on a limited region of the LV, which could
hinder its application to patients with variable LV geometries.124
Another potential limitation is the need for manual tracking, which
introduces the problems of time-consuming analysis and potential
interobserver variability. However, new indices and calculations
partly overcome these limitations through the analysis of 2D and
3D midwall mechanics, introducing the concepts of 2D and 3D
midwall EF.125,126 Finally, advanced echocardiographic techniques
are modifying the understanding of the hypertensive heart. Distur-
bances of longitudinal strain of the endocardial layer precedes the
alteration of circumferential strain, which is attributed to the
midwall layer.127 This is important because LV longitudinal
dysfunction plays a role in mediating the effect of LV geometry on
LV diastolic impairment.116
Tissue Doppler assessment of systolic
function
Tissue Doppler was the first widely available myocardial imaging
technique, and is credited with improving the feasibility of longitudin-
al ventricular function measurement. Several studies have shown
tissue Doppler—using either pulsed-wave or colour mapping—to
be a reliable tool for the assessment of LV systolic function. This
method has been validated against other methods for the assessment
of myocardial systolic performance and regional coronary blood
flow, as well as with histological findings.128 – 131 Its high temporal
resolution enables accurate determination of myocardial velocity
and acceleration even when overall image quality is deficient and
endocardial delineation is poor.132,133 Technical considerations
related to tissue Doppler have been considered in depth in an ASE/
EAE consensus statement, and will not be replicated here.134 In
hypertensive heart disease, the tissue relaxation velocity (e′) is
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reduced compared with normal, but to a much lesser degree than it is
in other hypertrophic situations such as hypertrophic cardiomyop-
athy and infiltrative disorders such as amyloidosis.
To obtain a reliable signal, the tissue Doppler sample volume
should be placed at the edge of the mitral annulus, trying to maintain
the volume line in the direction of the mitral annulus excursion to
avoid velocity underestimation or missing information on tissue
motion. The recommended Doppler velocity range is usually
+15–20 cm/s, but can be adjusted to the lowest possible without
generating aliasing. The main parameter for systolic performance
that can be extracted from tissue Doppler evaluation is s′, which
can be identified as a wave signal in the direction of the apex
and initiated immediately after the QRS complex. Among tissue
Doppler parameters, s′ has shown the best correlation with LVEF
and significant clinical outcomes such as rehospitalization and
reduced survival130,135, although measurements at the septal and
lateral side in the apical four-chamber view have proved to
produce good results (s′ , 7 cm/s showing 93% sensitivity and
87% specificity to identify patients with LVEF ,45%). Other
authors have reported slightly higher diagnostic power with mea-
surements at six sites from the apical four-chamber, two-chamber
and long-axis views (six-site average s′ . 5.4 cm/s showing 88%
sensitivity and 97% specificity for LVEF .50%).128,130
In the setting of hypertensive patients, tissue Doppler measured s′
helps differentiate physiological LVH in athletes from hypertrophic
cardiomyopathy, and the latter fromLVHsecondary tohypertension.
Four-site measured mean s′ , 9 cm/s has shown to discriminate
physiological from pathological LVH with a sensitivity of 87% and a
specificity of 97%.136 Other studies have pointed out that hyper-
trophic cardiomyopathy patients have lower s′ values and higher
heterogeneity than hypertensive LVH.137
It is important to note that tissue Doppler relies completely on
the detection of motion. This needs to be taken into consideration,
since a potential limitation of this tool is the detection of myocar-
dial motion occurring due to passive movement, such as swinging
or tethering motion, instead of active myocardial contraction,
potentially leading to either an over- or underestimation of LV sys-
tolic function. In addition, the use of deformation imaging in hyper-
tensive heart disease has moved attention from midwall to
longitudinal (and hence subendocardial) function. Impairment of
longitudinal function always precedes the depression of LVEF
in hypertensive patients, and may be a guide to the presence of
fibrosis. Finally, tissue Doppler parameters are influenced by age
and sex.138
Assessment of myocardial function
by strain
Strain, strain-rate, and twist imaging (deformation imaging) are rela-
tively recent non-invasive methods for the assessment of regional
and global myocardial function, allowing discrimination between
active and passive myocardial tissue movement.139 Assessment of
strain and twist is extracted from images using the commercially avail-
able software, providing sensitive echocardiographic measures to
detect early subclinical evidence of ventricular dysfunction. This in-
formation can be gathered using tissue Doppler echocardiography
or speckle tracking,140 and has been described in detail in a recent
ASE/EACVI Consensus Statement.134 The measurement of strain
has been well validated with sonomicrometry,141 three-dimensional
tagged CMR,142 and cyclically compressed tissue-mimicking gelatin
phantom.143 Among the different deformation (strain) components,
longitudinal strain has gained an important value in this context. Lon-
gitudinal strain corresponds to the function of the endocardial layer
of myocardium, where longitudinal fibres are subjected to the nega-
tive impact of early development of fibrosis in hypertensive heart
disease.144 However, strain is highly sensitive to increased afterload,
and the relative degree of impairment of strain that is due to LV dys-
function vs. that is due to hypertension may be difficult to tease apart.
Reported normal values of global longitudinal strain vary from215.9
to 222.1% (mean, 219.7%; 95% CI 220.4 to 218.9%).145
This technique has been used to differentiate between different
causes of increased wall thickness. In addition to the degree of reduc-
tion of strain, the pattern of strain reduction is also important. For
example, amyloidosis is characterized by a particular pattern of
apical sparing not seen in other causes of hypertrophy,146 and hyper-
trophic cardiomyopathy is associated with deformation disturbances
at the site of hypertrophy with less abnormal deformation elsewhere.
The morphology of the longitudinal strain signal may also be import-
ant in recognizing myocardial scarring.Acharacteristic doublepeak in
the strain-rate signal has been identified in patients with scar tissue
associated with hypertrophy in hypertrophic cardiomyopathy,
Fabry’s disease, and aortic stenosis.147 This phenomenon presumably
reflects a degree of post-systolic shortening in the presence of fibro-
sis. Thus, although the functional markers are non-specific for the
diagnosis of hypertensive heart disease, they may demonstrate spe-
cific patterns and degrees of disturbance that distinguish between
hypertensive hypertrophy and other aetiologies, as well as recogniz-
ing the contribution of fibrosis. Longitudinal strain can be even used
to differentiate hypertensive heart disease from functional myocar-
dial changes in the athlete’s heart.127
Finally,CMRmaybeused forquantifyingmyocardial function, using
techniques that measure myocardial deformation. It is not clear that
these are superior to the echo techniques, as they are obtained at
lower temporal resolution. This may be particularly pertinent for
the identification of post-systolic shortening or disturbances of dia-
stolic function.
Prognostic significance of LV function
in hypertension
Chamber function
The prognostic significance of LV function is well established. It
is known that heart failure is a common consequence of hyper-
tension and in the majority of patients is related to impaired LV
systolic function, which accounts for about half of heart failure
cases.148,149 However, hypertension is not necessarily associated
with a reduced systolic function—this may be increased in the
initial stages.150 EF, a global measure of LV chamber function, is
used to distinguish systolic (EF ,50%) from diastolic HF (EF
≥50%), and is a reliable method for predicting primary cardiac
events and cardiac mortality in individuals. Endocardial FS is a good
measure of LV global systolic function; however, its use in the
setting of hypertension is discouraged, especially in the presence of
LV hypertrophy. As discussed above, both EF and FS are constrained
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because theymeasure endocardial function, whereas the true param-
eter of interest is midwall function. In addition, the limited field of
view with M-mode leads to an under-appreciation of regional wall
motion. Wall motion abnormalities can identify adults without
known cardiovascular disease (CVD) who are at 2.4- to 3.4-fold
higher risk of CVD morbidity and mortality.151
In contrast, 2D strain has been shown to be abnormal in hy-
pertensive patients with normal EF,127 as well as in pre-
hypertension.152 Although EF is accepted as a prognostic marker,
its prognostic value in the range that is close to normal is limited.
Strain does not seem to share this limitation,66 and this may be of
value in discerning the progression from hypertensive heart
disease to heart failure.
LV midwall function in hypertension
The calculation of LV midwall shortening (FSMW) has been discussed
above. Depressed FS is associated with increased LV RWT and
LVM, and FS may be impaired in hypertensive patients with normal
LVEF.153 FS predicts adverse outcomes,108 but there are limited
data about the relative ability of FS to predict cardiovascular events
independent of known established risk factors (LVM and BP).122
Indeed, some authorities question the incremental information
provided by the assessment of LV systolic function to LVM in
hypertensive heart disease.154 Nor has it been shown that improved
treatment of LV chamber systolic function (in those with a normal EF
and depressed LV FSMW) is associated with lower CVD morbidity
and mortality, independent of change in BP and LVM in treated
hypertensive patients.122
Recommendations
Assessment of LV function provides incremental information to the
assessment of LVM in hypertensive subjects and should be a
component of the echo report in all hypertensive patients.
LVEF remains the most widely reported measure of global LV function.
Global longitudinal strain has shown a prognostic value in patients with
near-normal EF, where the prognostic information from EF is less
useful.
Diastolic function in hypertension
Assessment of mitral inflow
Acquisition and measurements
Previous position statements have provided guidance on the tech-
nical requirements for diastolic function evaluation,155 including
sample volume size and location, sweep speed, and respiratory
phase. Mitral inflow measurements should include early peak filling
(E velocity), late peak atrial filling (A velocity), E/A ratio, deceleration
time (DT) of E velocity, and isovolumic relaxation time (IVRT).
Normal values
Normal values are reported in Table 7. Diastolic filling patterns are
classified by the combined quantitative analysis of E/A ratio, DT,
tissue Doppler, and LA volume in particular.156 With increasing
age, impairment of LV relaxation leads to low E velocity, high A
velocity, and decreased E/A ratio with prolongation of DT.157
Delayed relaxation occurs in uncomplicated systemic arterial hyper-
tension. Because of the load dependence of these measurements, the
pseudonormal filling pattern cannot be recognized on the basis of
simple evaluation of mitral inflow pattern, but needs additional
assessment during a Valsalva manoeuvre (low reliability) or the
additional assessment of pulmonary venous flow (intermediate
reliability) or pulsed Tissue Doppler-derived e′ velocity of the
mitral annulus (highest reliability). The detection of LA enlargement
is a marker of longstanding increase of LA pressure in hypertensive
heart disease.
Prognostic significance of mitral inflow patterns
The main prognostic importance of Doppler-derived LV filling is in
patients with systolic HF, where mitral inflow measurements correl-
ate with LV filling pressure, functional classes, and prognosis.158
In hypertension, normal in-treatment transmitral flow pattern
indicates a low risk for heart failure (HR 0.22 [95% CI 0.05–0.98,
P ¼ 0.048), independent of blood pressure.159 However, the inter-
mediate ranges of E/A ratio (from 0.6 to 1.5) do not stratify prognosis
in hypertensive subjects,17 probably because normal and pseudonor-
mal patterns are combined. Although antihypertensive treatment in
patients with LVH results in improvement of mitral inflow patterns,
this was not associated with reduced cardiovascular morbidity and
mortality.159
Tissue Doppler assessment of myocardial
diastolic function
Acquisition and measurements
Guidance on the technical requirements for tissue Doppler acquisi-
tion has been provided regarding sample volume location, angulation,
and respiratoryphase.160 Inhypertensiveheart disease, earlydiastolic
tissue velocity (e′) is reduced by reduction in LV relaxation. However,
it is also influenced by preload, systolic function, and LV minimal pres-
sure. The other basic measured parameter is late (atrial) diastolic
velocity (a′, influenced by LA function and LV end diastolic pressure).
E/e′ has been used as a measure of LA driving pressure or LV filling
pressure.161 However, there are a number of situations where e′
and E/e′ may be misleading,162 including reduced septal e′ velocity
due to inferior infarction or annular calcification, and increased trans-
mitral E velocity due to mitral regurgitation. Averaging septal and
lateral e′ may reduce some of this variability, but does not address
all of the limitations of the parameter.
Normal values
Similar to mitral inflow velocity, e′ values diminish with age (Table 7).
For the evaluation of LV global diastolic function, it is recommended
to record and measure tissue Doppler signals at both septal and
lateral mitral annulus and obtain their average.156 The rationale of
averaging septal and lateral values is derived from the observation
that e′ velocities are significantly greater at the lateral location than
at the septal placement of the annulus. While single-site measure-
ments can be used in the presence of globally normal or abnormal
LV systolic function, the average of the two site measurements is
particularly important in patients with LV regional dysfunction.
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Prognostic significance of tissue Doppler
parameters
Annular tissue velocities are strongpredictors of outcome in avariety
of settings. In a 2-year follow-up study of .500 patients, 35% of
whom had hypertension, Wang et al.163 showed that a pulsed-wave
e′ of ,3 cm/s was associated with a 5.3-fold increment of hazard.
As these data were gathered from colour-coded tissue Doppler,
they represent unusually low values for e′ velocity, analogous to
pulsed-wave signals in the range of ,5 cm/s. Similar findings have
been described using an e′ of ,3.5 cm/s in hypertension and LV
hypertrophy.164 It has to be acknowledged, however, that velocities
,5 cm/s are quite extreme, and less usual in hypertensive heart
disease than hypertrophic cardiomyopathy or infiltration.
Likewise, E/e′ has prognostic implications, with E/e′ ≥ 15 having
been shown to add an independent prognostic value to B-type natri-
uretic peptide and EF.165 Although studies have been more focused
on post-MI and heart failure than hypertension, Sharp et al.166 recent-
ly demonstrated the prognostic value of E/e′ ratio in uncomplicated
hypertensive patients, independent of LVM. On these grounds, the
2013 ESC/ESH guidelines on arterial hypertension promote the
use of E/e′ in the detection of cardiac target organ damage in hyper-
tensive heart disease.167
Recommendations
All echocardiography reports in patients with hypertension should
include specific comments about diastolic function grade, left atrial
volume, and about normal vs. elevated LV filling pressure (usually
based on E/e′).
Cardiac impact of hypertension
treatment
LV hypertrophy regression
LV hypertrophy represents an important end-organ consequence of
hypertension. Population-based studies using echocardiography
have demonstrated hypertrophy to be closely linked with adverse
events,42,107 including stroke, renal impairment, left ventricular dys-
function, atrial and ventricular arrhythmias, and sudden cardiac
arrhythmia or premature death.168 The eventual development of
complications from LVH represents long-term effects that are too
final to guide clinical therapy, and too slow as a research outcome.
Therefore, LVH has been proposed as a surrogate marker of
outcome. LVH has been shown to be reversed or prevented by a
variety of haemodynamic, non-haemodynamic, and pharmacological
factors.169
Nonetheless, the use of repeat imaging to document changes in
LVM has been difficult to incorporate into standard practice for at
least two reasons. The first relates to the inherent variability of
LVM measurements with echocardiography. While reductions in
the ventricular mass have been associated with improved outcome
across populations, in studies which identify regression of hyper-
trophy on an individual basis, large populations are required to over-
come the variability of these measurements. Thus, while the
association between LVH regression and improved outcome has
now been recognized in a number of studies,170 because of the
test–retest limitations of echocardiography, CMR may be more ac-
curate to demonstrate this effect.94 This role of echocardiography
may be improved by the enhancement and clinical use of 3DE,
which has been validated against CMR.53
The second limitation is that hypertrophy occurs in 36–41% of
hypertensive subjects,171 but hypertension is not the only cause of
this problem. Hypertrophy may be influenced by obesity, diabetes,
the metabolic syndrome, and renal impairment, amongother aetiolo-
gies. Progression of the condition may lead to ischaemia, both due to
concurrent coronary artery disease as well as failure of vascular pro-
liferation to match myocardial proliferation, vascular compression,
and the effect of raised LV pressure on subendocardial flow.
Change in LV geometry
Changes in LV geometry have been associated with improved blood
pressure control, reflecting the impact of afterload on LV remodel-
ling. Again, however, the variability of 2DE has been a limitation
in understanding the association of reverse remodelling with
improved survival, using conventional techniques. Recent evidence
has indicated that use of CMR (or potentially 3DE) provides a
means of measuring sphericity on a serial basis, and therefore docu-
ments remodelling changes in response to blood pressure control.
Change in systolic function
LV systolic function, measured by EF, is normally preserved until late
in the course of hypertensive heart disease. Indeed, although EF is
associated with outcome in patients with moderate LV impairment,
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Table 7 Normal Doppler values for diastolic measurements (modified from Nagueh et al.156)
Measurement Age group (years)
16–20 21–40 41–60 >60
IVRT (ms) ,32, .68 ,51, .83 ,60, .88 ,73, .101
E/A ratio ,0.98, .2.78 ,0.73, .2.33 ,0.78, .1.78 ,0.6, .1.32
DT (ms) ,104, .180 ,138, .194 ,143, .219 ,142, .258
Septal e′ (cm/s) ,10.1 ,10.1 ,7.6 ,6.2
Lateral e′ (cm/s) ,13 ,14 ,11.5 ,5.9
For septal E/e′ , values of ,8 can be considered normal and .15 are elevated, with 8–15 being ambiguous.
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the association of mild or borderline impairment with adverse
outcome has been more difficult to show. Likewise, volumetric and
EF changes in heart failure have been associated with improvements
in outcome,172,173 but this information is difficult to apply to hyper-
tensive heart disease in which EF is either preserved or borderline
reduced.
Change in diastolic function
Diastolic dysfunction, particularly in the later stages of hypertensive
heart disease, is associated with prognosis.174 However, most
patients with hypertensive heart disease have grade I diastolic dys-
function, and changes in this finding are intrinsically ambiguous.
When the E/A ratio is ,1 and moves towards unity, this may occur
because of recovery of function and improvement in LV suction, or
it may occur because of raised filling pressures and transition of
grade I to grade II disease. Documentation of changes in diastolic
function is difficult to interpret in any patient, and no less in those
with hypertensive heart disease. In a randomized study of angiotensin
receptor blockade, no significant change in e′ was witnessed between
valsartan and the control group.175 Nonetheless, other studies have
shown that improvements in LV geometry after treatment in hyper-
tensive patients with ECG evidence of LV hypertrophy have been
associated with parallel improvements in Doppler-derived indices
of diastolic function.176
Recommendations
While echocardiography has been key in demonstrating the beneficial
effects of hypertension treatment in large cohort studies, routine
reassessment of echocardiograms to examine treatment response in
hypertensive subjects is not recommended, due to the limited
reproducibility of measurements on an individual patient basis.
Follow-up echocardiograms may be of value to assess changes in
symptom status.
Echocardiography in clinical
management of hypertension
Stratification of risk in hypertension
The value of transthoracic echocardiography is recognized in the
2013 ESC/ESH guidelines,167 where it is listed as a class II indication
(level of evidence B) for cardiovascular risk assessment in asymptom-
atic adults with hypertension.177 Transthoracic echocardiography
received a high appropriate use criteria score of 8 (scale 1–9) for
the initial evaluation of suspected hypertensive heart disease.178 In
this document, LV hypertrophy, LV diastolic dysfunction, and LA
enlargement are described as specific signs of hypertensive
heart disease. LV hypertrophy is recognized as evidence of target
organ damage in hypertension by the Joint National Committee for
the prevention, detection, and evaluation of high blood pressure
(JNC 7) of the National High Blood Pressure Education Program
(National Heart Lung and Blood Institute).179
In patients with hypertension, the type of LV remodelling (concen-
tric remodelling, eccentric hypertrophy, and concentric hyper-
trophy) is predictive of the incidence of CV events. In particular,
the presence of LVH on echocardiography identifies hypertensive
heart disease with a higher sensitivity and specificity compared
with electrocardiography. Several population cohort studies have
shown that LVH is predictive of cardiovascular and all-cause mortal-
ity, independent of blood pressure, and across all racial groups that
have been studied. In the predominantly white population of the Fra-
mingham Study, for every 50 g/m2 higher left ventricular mass index,
there was a relative risk of death of 1.73 (95% CI 1.19–2.52), inde-
pendent of blood pressure level.107 In African-Americans enrolled
in the ARIC study, LVH was associated with an increased risk of
cardiovascular events (HR of 1.88 in men and 1.92 in women).180
Similarly, for Native Americans enrolled in the Strong Heart Study,
echocardiographic LVH also had additive discriminatory power
over ECG LVH; the prevalence of LVH on echocardiography was
9.5% and was associated with a seven-fold increase in cardiovascular
mortality and a four-fold increase in all-cause mortality.181 Hispanic
Americans showed a similar association of LVH and CVD mortal-
ity.182 International studies have also confirmed a similar risk for
CVD in hypertensive patients with LVH.183 Concentric LVH on
echocardiography identifies a high risk phenotype with abnormal
flow-mediated dilation and decreased myocardial flow reserve.184
In symptomatic adults with hypertension, the echocardiogram
provides additional assessments for systolic and diastolic dysfunction,
as well as evaluation of wall motion abnormalities to detect under-
lying coronary artery disease. The use of echocardiography during
treadmill or pharmacological testing is indicated in hypertensive
patients with symptoms suggesting CHD and/or to estimate progno-
sis in patients with known concomitant coronary artery disease as
well as thosewith known or suspectedvalvularheart disease. Patients
with LVH, as well as related problems (abnormal resting ECG, left
bundle-branch block, electronically paced rhythm, and digoxin
therapy), also warrant pharmacological stress echocardiography.177
Investigation of chest pain symptoms
Chest pain in patients with hypertension may signify concurrent cor-
onary artery disease or may simply reflect subendocardial ischaemia
due to LV hypertrophy and increased afterload. The diagnosis of cor-
onary artery disease has particular challenges in this setting, because
‘false-positive’ results may occur when subendocardial ischaemia
causes abnormal stress ECG or myocardial perfusion scan in the
absence of flow-limiting epicardial coronary disease.185 A normal
stress electrocardiogram, performed to a high workload, has a high
negative predictive value, but an abnormal or ambiguous test war-
rants further evaluation. There is some evidence in favour of prefer-
ential use of stress echocardiography for this purpose, because
stress-induced wall motion abnormalities are highly specific for cor-
onary artery disease, while perfusion defects in hypertensive patients
may arise from abnormal myocardial flow reserve not due to epicar-
dial coronary disease.186 The lack of specificity of the coronary flow
signal for epicardial coronary artery disease is also a problem when
stress echocardiography is combined with the assessment of coron-
ary flow reserve in hypertensive patients.187 Finally, although hyper-
tensive patients are at increased risk of coronary artery disease,
screening for coronary disease is not recommended in asymptomatic
patients because of the risk of false-positive results and uncertain
management responses.
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Role in decision to initiate treatment
Effects of antihypertensive agents on LVM and other echocardio-
graphic surrogate endpoints (e.g. LA size and diastolic function)
have been extensively studied. Several large studies sponsored by
the National Institutes of Health and the US Veterans Administration
Cooperative Studies program have evaluated the effects of antihy-
pertensive monotherapy. In general, it appears likely that there are
differences between the efficacy of antihypertensive drugs and
their effects on LVH. LVH regression does not adversely affect
cardiac function and may be associated with improvements in diastol-
ic function. However, although the finding of increased LVM on
echocardiography could potentially guide selection of initial or
intensity of therapy in hypertensive patients, JNC 7 recommenda-
tions do not risk stratify patients for treatment on the basis of
target organ damage. Current guidelines recommend the use of
combination treatment to get blood pressure to goal, thus blood
pressure remains the primary target of therapy.
A part of the problem with getting a more central role for echo-
cardiography to guide therapy is that despite the adverse prognosis
associated with LVH in hypertension, there are inconsistent data
from numerous studies that have evaluated the comparative
efficacy of specific antihypertensive agents in LVH regression, as
well as survival benefits associated with LVH regression. In a
meta-analysis of 39 trials of antihypertensive therapy, angiotensin-
converting enzyme inhibitors were the most effective agents,
leading to a 13.3% reduction in LVM compared with 9.3% for
calcium channel blockers, 6.8% for diuretics, and 5.5% for beta-
blockers.188 However, in a comparison of enalapril and long-acting
nifedipine in patients with essential hypertension, the PRESERVE
(Prospective Randomized Enalapril Study Evaluating Regression of
Ventricular Enlargement) trial, systolic and diastolic pressures, as
well as LV mass were reduced to a similar degree with both
agents.189 On the other hand, the LIFE (Losartan Intervention For
Endpoint Reduction in Hypertension) trial echocardiographic sub-
study demonstrated superior LVM reduction (21.7 g/m2) in patients
treated with the angiotensin receptor blocker losartan compared
with those treated with the beta-blocker atenolol (17.7 g/m2).190
Finally, despite a 20% incidence of LVH regression with placebo,
diuretic therapy with chlorthalidone and hydrochlorthiazide, re-
spectively, demonstrated greater LVH regression over alternative
agents in both the TOMHS (Treatment of Mild Hypertension
Study) and Department of Veterans Affairs Cooperative Study
Group on Antihypertensive Agents.191,192 Similarly, left atrial size
(itself a predictor of adverse outcomes31) was reduced with hydro-
chlorothiazide.193
In the recently defined category of pre-hypertension (systolic
blood pressure 130–140 mmHg and/or diastolic blood pressure
80–90 mmHg), JNC 7 recommends intense lifestyle modification
in such patients. Clinicians may obtain echocardiography to evaluate
the presence of LV hypertrophy in such patients with pre-
hypertension, particularly where there is a strong family history of
hypertension and cardiovascular complications including stroke,
heart failure, or dialysis. The community practice consensus is that
the presence of LVH in such patients should lead to more aggressive
approaches to lifestyle modification. There is increasing recognition
that data on target organ involvement, including echocardiographic
LVH, may be important for young adults whose lifetime risk for
hypertension is currently underestimated by most risk stratification
models. However, no studies have examined whether a patient’s
knowledge of echocardiography demonstrating LVH will improve
adherence to lifestyle modifications or pharmacological treatment
of hypertension.
According to the National Health Service and National Institute
for Health and Clinical Excellence (NICE) recent guideline update
on the clinical management of primary hypertension in adults,
there is uncertainty about how to assess the impact of blood pressure
treatment in people aged ,40 years with grade 1 hypertension and
noovert targetorgandamageorCVD.194 Inparticular, it is not known
whether those with untreated hypertension are more likely to
develop target organ damage and, if so, whether such damage is re-
versible. The writers of the NICE guideline further observe that
target organ damage as surrogate or intermediate disease marker
for CVD or hypertensive heart disease is the only indicator that is
likely to be feasible in younger people because traditional clinical
outcomes are unlikely to occur in sufficient numbers over the
timeline of a typical clinical trial.
Role in decisions to intensify treatment
The decision to intensify treatment of hypertension is currently
guided by monitoring of clinic as well as home blood pressures. In
patients who have hypertensive heart disease with LVH and
normal systolic function, the value of periodic echocardiographic
follow-up is not established; the Appropriate Use Task Force gave
a score of 4 (may be appropriate) based on insufficient data for a
stronger recommendation, regarding the re-evaluation of known
hypertensive heart disease without a change in clinical status or
cardiac examination.178 However, echocardiography may be
helpful in several scenarios. Patients with hypertensive heart
disease who become symptomatic require follow-up echocardiog-
raphy to evaluate systolic and diastolic function. Dissociation
between blood pressure measurements and LV hypertrophy is an
indication for further testing. The detection of high blood pressure
without hypertrophy should lead to consideration of overesti-
mation of the severity of hypertension, including ambulatory
blood pressure monitoring or measurement of central aortic pres-
sure.195 When there is apparent LV hypertrophy in the setting of
apparent blood pressure control, more detailed blood pressure
evaluation (e.g. for masked hypertension) or identifying other
causes of wall thickening such as infiltrative diseases should be
considered.
Use of echocardiography to monitor
response to antihypertensive treatment
There is no current indication for the use of echocardiography to
routinely monitor antihypertensive therapy, except as indicated
and described in the section above for symptomatic patients or for
patients with poor control of blood pressure. A recent intersocietal
consensus document178 on the appropriate use of echocardiography
in clinical practice characterized its routine use for patients with
hypertension without symptoms or signs of heart disease as ‘rarely
appropriate’ with a value score of 3 out of 10.
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Relevance of hypertension to
echocardiographic interpretation
Afterload is an important determinant of the assessment of cardiac
function from ejection phase indices. Consequently, hypertension
may have an important effect on the assessment of LV function in a
variety of conditions. For example, an increment of blood pressure
between visits may lead to an apparent deterioration of LV function
when serial echocardiograms are being performed during chemo-
therapy or in the evaluation of valvular heart disease. In the assess-
ment of aortic stenosis, arterial hypertension and the stenotic valve
behave like serial resistors, and their combined impedance may
explain symptom status.196
Likewise, in stress echocardiography, hypertension—especially a
hypertensive response to stress—may provoke wall motion abnor-
malities or global LV dysfunction in the absence of coronary
disease.197 However, the impact of hypertensive LVH is probably
less than in perfusion scintigraphy, where abnormal coronary flow
reserve may produce false-positive perfusion abnormalities in the
context of normal wall motion.198
Recommendations
At present, decisions regarding the initiation, intensification, or
monitoring of response to antihypertensive therapies are made
based on clinical parameters.
Given the progressive nature of hypertensive cardiomyopathy, periodic
evaluation of cardiac function and morphology by echocardiography
may be warranted, especially if symptoms change.
Recommendations for clinical
laboratories
The value of echocardiography as a research tool in hypertension is
uncontested. In a relativelyshort time, it hasdefined the cardiac struc-
tural and functional effects of hypertension, determined the preva-
lence of LVH and LV remodelling, determined the cardiac effects of
antihypertensive therapy, and in epidemiological studies, provided
fundamental insights into the relationships between blood pressure,
genetic susceptibility, and LV mass. However, although it has been
suggested that treatment choices in individual patients should be
guided by echocardiographic findings, the value of echocardiography
in the clinical management of hypertension is unproven.
The benefits of echocardiography will depend on its value in
affecting treatment decisions, and in early identification and interven-
tion in patients at risk who would not otherwise be treated.
Moreover, demonstration of a value requires that the impact of
echocardiography on clinical decisions is accompanied by improve-
ment in patient outcome. Importantly, any consideration of the
utility of echocardiography is contingent upon its reliability for the as-
sessment of target measures such as LVM. However, little informa-
tion is available on the impact of echocardiographic data on
physician behaviour, or on patient outcomes in hypertension.
Previously, World Health Organization-International Society of
Hypertension (WHO-ISH) suggested that drug treatment could be
withheld in hypertensive individuals with low cardiovascular risk
based on non-echocardiographic criteria. However, echocardio-
graphic findings in such individuals increases risk classification in
29% of such cases,199 suggesting a role for echocardiography in risk
profiling. However, recommendations for drug therapy at lower
blood pressure levels may have made this application of echocardiog-
raphy moot.
Another important limitation on the wider use of echocardiog-
raphy is cost, both relative to benefit, and in competition foreconom-
ic resources. In the USA alone, approximately 76.4 million adults have
hypertension.200 At even the arguably modest current Medicare/Me-
dicaid reimbursement for echo of $238, one echo per patient with
hypertension would cost $181.2 billion. Justification for this expend-
iture as an additional billable item would be difficult to provide.
However, the development of hand-held ultrasound would allow
suitably trained practitioners to obtain LV wall thickness and dimen-
sion information as part of the office visit. The effectiveness of
this strategy remains unproven, especially in the light of training
requirements, concern about interobserver variability, lack of stand-
ard quality assurance standards, and the increase in time for an office
visit.
Given the above considerations, it has been recommended that
echocardiography be reserved for those individuals with hyperten-
sion in whom hypertensive cardiac disease or cardiac disease in asso-
ciation with hypertension comorbidities is suspected. In such cases, a
complete 2D and Doppler study should be performed, and the study
not limited to evaluation of LVM/LVH. While calculation of LVM can
readily be performed utilizing standard methods,46 variability can be
quite large, and current evidence does not support using LVM meas-
urement to either initiate or modify hypertension treatment.
Recommendations for research
studies and clinical trials
Table 8 lists some potential areas where echocardiography (or other
imaging) may help to guide management decisions in hypertension.
The role of imaging in these settings is unproven and warrants
further study.
Acquisition and interpretation of echocardiograms for research
purposes in hypertension poses some special challenges. Even for
clinically experienced sonographers, there is a significant learning
curve present in recording technically adequate echocardiographic
studies for the assessment of LVM, particularly in older subjects. In
a Framingham analysis of M-mode echocardiograms performed in
over 6000 subjects aged 17–90, the ability to record acceptable
quality echocardiograms in subjects older than 60 years rose from
a minimum of 28% during the first 5 months of the study to a
maximum of 74–81% during studies 2 years later. Hence, echocardi-
ography ‘drop-outs’ may not be randomly distributed, leading to the
possibility of bias in data interpretation. Two-dimensional echocar-
diographic measurements were even more problematic than
2D-guided M-mode.
In previous large echocardiography trials, major differences in
echo quality have existed between field centres. For example, in a
15 centre ventriculo-arterial trial of antihypertensive monother-
apy,192 the percent of readable echocardiograms for LVM varied
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from30 to 85%. This was not due to differences between centres in
the proportion of easy or difficult patients. While the use of subopti-
mal equipment in some cases contributed to poor studies, the inter-
centre differences were mostly because of variation in technical
performance. Importantly, extensive previous clinical experience in
echocardiography was no guarantee of high-qualityechocardiograms
for research purposes.
There is potential for differences in image acquisition styles that may
exist between field centres in epidemiology studies, potential effects of
instrumentation, continuing improvement in quality images obtained
with newer generations of echo machines, and temporal intrareader
drift in echo measurements and interpretations (e.g. LV walls may be
read as thicker, or thinner at the beginning than the end of the clinical
trial or observational study). All of these may produce not just large
random variability in measurements and qualitative assessments, but
substantial biases. For example, a temporal drift where readers might
tend to read smaller wall thicknesses after months to years of experi-
ence with the study and patients receiving several treatments in the
absence of a placebo control (common if not ubiquitous in clinical
hypertension trials) may lead to the mistaken conclusion that both
treatments are associated with decreased LVM and decreases in the
proportion of individuals with LVH.
Several principles learned from clinical trials are applicable for echo-
cardiography.201 The acquisition of reproducible, correctly oriented
images requires sonographer training. Monitoring of study quality is im-
portant. The inclusion of ‘control’ subjects is a protection against appar-
ent changes due only to regression to the mean. The use of sample
echocardiograms is a means of ensuring that all team members are
applying the same methodology, and to prevent ‘drift’ over time.
Recommendations for echocardiography
in hypertension clinical trials
Given the large confidence intervals that may exist for measurement
of LVM, it could be argued that treatment trials should recruit
participants with markedly increased LVM. However, selection of
participants with values for LVM values substantially above (or
below) the population mean can result in subsequent tests that
reflect regression to the mean. Therefore, higher than ‘true’ values
for LVM on an initial determination will tend to decrease on subse-
quent measurement. It is recommended that if possible, partition
values for LVM not be used as requirements for entry into the study.
If such values are used, then batch reading at completion of the
study (with continuous monitoring of studies for acquisition quality)
should be done. This may not be practical in long-term studies.
In creating categorical variables (e.g. LVH, LA enlargement, and ab-
normal annular tissue velocity), it is advisable when possible to use
comparative control subjects from the same study to generate parti-
tion reference values. This is often possible in observational or epide-
miologic studies, where participants without clinically prevalent
disease (or better still—free of subclinical disease as well) can be uti-
lized to derive partition values for continuous variables. Where those
values are affected by age, body weight, height, gender, etc.—refer-
ence values can be derived from regression models used to derive
a predicted value (with confidence limits) and express abnormality
of a parameter by determining its ratio to this predicted value.
However, this may not be possible in many clinical trials.
In large multicentre observational studies and clinical trials where
all studies are read by a single core laboratory, the volume of studies
can quickly become overwhelming. Special considerations exist re:
management of workflow, but also vetting of site sonographers, par-
ticipation in trial design, statistical power estimations, provision of
ongoing quality assurance and improvement, data transmission to
the statistical core, and issues regarding participant and investigator
clinical alerts for abnormal findings. Specific considerations regarding
core laboratory best practices have been described in a previous ASE
EACVI expert consensus statement.202,203
Conflict of interest: This report is made available by EACVI and
ASE as a courtesy reference source for members. This report con-
tains recommendations only and should not be used as the sole
basis to make medical practice decisions or for disciplinary action
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Table 8 Potential sources of contribution of echocardiography on clinical management
Clinical subset Echocardiographic target Finding Possible impact
Established hypertension LVM or LVH LVH Selection of neurohormonal blockade (ACE
inhibitors) or calcium blockers
Borderline hypertension
‘White-coat’ hypertension
LVM or LVH Persistent LVH with therapy
No LVH
Unequivocal LVH
Question adequacy of BP control, check ambulatory
BP, change drugs
Follow closely
Drug Rx
Haemodynamic profile Cardiac output and total peripheral
resistance
High output-low resistance
High resistance-low output
Beta-blocker, diuretics, calcium blockers, ACE
inhibitors, vasodilators
High risk for coronary
artery disease
Regional wall motion
Abnormality (RWMA)
RWMA present
RWMA and  LV function
Prior infarct-? Stress test
Consider angiography; drug selection—
‘anti-ischaemic’ antihypertensive drugs
Hypertension in the elderly Valvular disease, LV architecture Aortic stenosis
  Relative wall thickness,
small LV cavity
Caution with vasodilators, diuretics
Avoid diuretics; avoid vasodilators
LV, left ventricular; LVH, left ventricular hypertrophy; Rx, therapy; ACE, angiotensin-converting enzyme inhibition.
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against any employee. The statements and recommendations con-
tained in this report are primarily based on the opinions of experts,
rather than on scientifically verified data. EACVI and ASE make no
express or implied warranties regarding the completeness or accur-
acy of the information in this report, including the warranty of mer-
chantability or fitness for a particular purpose. In no event shall
EACVI and ASE be liable to you, your patients, or any other third
parties for any decision made or action taken by you or such other
parties in reliance on this information. Nor does your use of this in-
formation constitute the offering of medical advice by EACVI and
ASE or create any physician–patient relationship between EACVI/
ASE and your patients or anyone else.
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